Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
暂无分享,去创建一个
[1] M. Ringnér,et al. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. , 2006, Carcinogenesis.
[2] L. Chin,et al. Malignant melanoma: genetics and therapeutics in the genomic era. , 2006, Genes & development.
[3] D. Schadendorf,et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.
[4] D. Schadendorf,et al. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes , 2006, Melanoma research.
[5] N. Thomas. BRAF somatic mutations in malignant melanoma and melanocytic naevi , 2006, Melanoma research.
[6] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[7] D. Schadendorf,et al. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. , 2005, Carcinogenesis.
[8] Keith W. Vance,et al. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. , 2005, Cancer research.
[9] R. Mason,et al. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells , 2005, Melanoma research.
[10] B. Weber,et al. SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant , 2004, Cancer Research.
[11] J. Gray,et al. TBX3 and Its Isoform TBX3+2a Are Functionally Distinctive in Inhibition of Senescence and Are Overexpressed in a Subset of Breast Cancer Cell Lines , 2004, Cancer Research.
[12] Markus Ringnér,et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature , 2004, Oncogene.
[13] Keith W. Vance,et al. Tbx2 Directly Represses the Expression of the p21WAF1 Cyclin-Dependent Kinase Inhibitor , 2004, Cancer Research.
[14] Meenhard Herlyn,et al. BRAF as a potential therapeutic target in melanoma and other malignancies. , 2003, Cancer cell.
[15] M. van Lohuizen,et al. The T-box Repressors TBX2 and TBX3Specifically Regulate the Tumor Suppressor Genep14 ARF via a Variant T-site in the Initiator* , 2002, The Journal of Biological Chemistry.
[16] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[17] M. MacDonald,et al. TBX-3, the Gene Mutated in Ulnar-Mammary Syndrome, Is a Negative Regulator of p19 ARF and Inhibits Senescence* , 2002, The Journal of Biological Chemistry.
[18] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[19] Marc J. van de Vijver,et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers , 2000, Nature Genetics.
[20] Nello Cristianini,et al. An Introduction to Support Vector Machines and Other Kernel-based Learning Methods , 2000 .
[21] J. Seidman,et al. Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome , 1997, Nature Genetics.
[22] Corinna Cortes,et al. Support-Vector Networks , 1995, Machine Learning.
[23] B. Weber,et al. Advances in Brief SPRY 2 Is an Inhibitor of the Ras / Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V 599 E Mutant , 2004 .
[24] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.